Remicade (infliximab) - J&J
afimkibart (RG6631) - Roche
duvakitug (SAR447189) - Teva, Sanofi
obefazimod (ABX464) - Abivax
Humira (adalimumab) - AbbVie
Tremfya (guselkumab) - J&J
Omvoh (mirikizumab-mrkz) - Eli Lilly
tofacitinib - Generic mfg.
Stelara (ustekinumab) - J&J
Jyseleca (filgotinib) - Gilead
Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim
Simponi (golimumab) - J&J
Rinvoq (upadacitinib) - AbbVie
Entyvio (vedolizumab) - Takeda
Zeposia (ozanimod) - BMS
Velsipity (etrasimod) - Pfizer
tulisokibart (MK-7240) - Merck (MSD)
http://www.ncbi.nlm.nih.gov/pubmed/42595931
 
Brian G Feagan; Camilyn Cheng; Christopher Ma; Dhruv Gupte; Eileen Crowley; Jessica Le; John K MacDonald; Jurij Hanzel; Nidhi Rashmikant Suthar; Ruben J Colman; Vipul Jairath
 
Aug 15, 2026
 
Prev Next